Stock listing

BOATS:CMPX Compass Therapeutics, Inc. Stock

US listing (BOATS) of Compass Therapeutics, Inc. · home listing NASDAQ:CMPX

Follow Compass Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CMPX

$0.688 USD +0.077 (+12.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CMPX

Past year -85.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.641 – $0.730 USDNov 20, 2026
Volume
1.82M sharesNov 20, 2026
Market cap
$123.9M USDAt the close on Nov 20, 2026 · price × 180.1M shares outstanding
52-week range
$0.570 – $6.880 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$4.78M USDMedian day 2.52M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Compass Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CMPX · Home$0.688 USD+0.077 (+12.6%)1,823,677$0.671$0.730$0.641$0.611Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CMPX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.688+0.077+12.6%$0.671$0.730$0.6411,823,677
$0.611+0.004+0.7%$0.624$0.640$0.5941,788,200
$0.607-0.055-8.3%$0.644$0.662$0.5702,903,203
$0.662-0.112-14.5%$0.768$0.778$0.6602,042,843
$0.774-0.046-5.6%$0.830$0.830$0.7511,549,519
$0.820-0.010-1.2%$0.824$0.830$0.8001,842,834
$0.830-0.008-0.9%$0.853$0.855$0.8101,524,280
$0.838+0.001+0.1%$0.849$0.896$0.8302,118,377
$0.837+0.078+10.3%$0.797$0.845$0.7722,249,171
$0.759+0.074+10.8%$0.700$0.760$0.6711,849,895
$0.685-0.078-10.2%$0.764$0.771$0.6852,592,374
$0.763+0.010+1.3%$0.785$0.800$0.7541,861,925
$0.753-0.014-1.9%$0.783$0.792$0.7441,617,548
$0.768-0.019-2.4%$0.811$0.811$0.7502,114,525
$0.787+0.030+4.0%$0.756$0.797$0.7402,918,232
$0.756-0.004-0.5%$0.780$0.810$0.7512,025,282
$0.760+0.013+1.7%$0.745$0.775$0.7301,796,676
$0.747+0.0000.0%$0.752$0.785$0.7302,210,224
$0.747-0.014-1.8%$0.750$0.793$0.7412,231,672
$0.761-0.040-5.1%$0.781$0.807$0.7502,128,369
$0.802-0.013-1.6%$0.813$0.841$0.7802,173,546
$0.815-0.019-2.3%$0.822$0.845$0.8081,544,138
$0.833-0.002-0.2%$0.833$0.868$0.8221,883,132
$0.835-0.025-2.9%$0.870$0.889$0.8263,119,040
$0.860-0.037-4.1%$0.900$0.909$0.8602,038,934
$0.897+0.018+2.0%$0.860$0.905$0.8503,339,175
$0.879+0.022+2.6%$0.831$0.882$0.8224,969,084
$0.857-0.081-8.6%$0.931$0.938$0.8543,800,409
$0.938-0.055-5.6%$0.990$0.990$0.9204,436,731
$0.993+0.010+1.0%$0.993$1.050$0.9783,670,889
$0.983-0.037-3.6%$1.010$1.010$0.9577,042,690
$1.020+0.022+2.2%$0.980$1.055$0.9652,792,590
$0.998+0.037+3.9%$0.990$1.020$0.9407,286,326
$0.961+0.104+12.1%$0.910$1.000$0.89015,831,950
$0.857-0.044-4.9%$0.940$0.980$0.82920,754,221
$0.901-0.139-13.4%$1.030$1.055$0.90110,067,700
$1.040-0.060-5.5%$1.100$1.100$1.0205,656,969
$1.100-0.010-0.9%$1.125$1.150$1.0903,500,547
$1.110-0.020-1.8%$1.150$1.150$1.1003,704,884
$1.130-0.005-0.4%$1.170$1.195$1.1203,532,924
$1.135-0.035-3.0%$1.170$1.170$1.1004,539,648
$1.170-0.070-5.6%$1.220$1.230$1.1307,693,255
$1.240-0.580-31.9%$1.250$1.440$1.15027,202,789
$1.820-0.080-4.2%$1.880$1.880$1.8002,987,340
$1.900+0.050+2.7%$1.860$1.900$1.8108,210,036
$1.850+0.020+1.1%$1.880$1.940$1.8402,515,917
$1.830-0.020-1.1%$1.870$1.895$1.8002,242,999
$1.850-0.110-5.6%$1.980$1.980$1.8502,440,059
$1.960-0.040-2.0%$2.025$2.040$1.9602,278,976
$2.000-0.050-2.4%$2.080$2.090$1.9554,828,614
$2.050-0.130-6.0%$2.170$2.170$2.0402,541,061
$2.180-0.030-1.4%$2.220$2.249$2.1702,614,911
$2.210-0.170-7.1%$2.320$2.325$2.2002,428,040
$2.380+0.010+0.4%$2.340$2.445$2.3302,548,324
$2.370-0.060-2.5%$2.440$2.440$2.3452,559,952
$2.430+0.120+5.2%$2.310$2.460$2.3102,539,819
$2.310-0.080-3.3%$2.370$2.395$2.2901,512,903
$2.390-0.010-0.4%$2.400$2.400$2.3103,523,042
$2.400-0.120-4.8%$2.510$2.510$2.4002,567,637
$2.520+0.090+3.7%$2.440$2.530$2.4001,941,408
$2.430-0.100-4.0%$2.510$2.520$2.4101,445,009
$2.530+0.130+5.4%$2.400$2.550$2.3902,295,274
$2.4000.0000.0%$2.420$2.430$2.320974,876
$2.400+0.040+1.7%$2.390$2.450$2.3302,032,331
$2.360-0.120-4.8%$2.420$2.455$2.3102,179,350
Ticker
BOATS:CMPX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Compass Therapeutics, Inc. news

Compass Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 104 in all · newest Nov 9, 2026 · oldest 2021
Calls
1 call with a replay · 1 with a transcript · latest Aug 11, 2025
Decks
8 decks · latest September 2026

Where Compass Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CMPX · Home listingNASDAQUnited StatesUSD
BOATS:CMPX · This pageBOATSUnited StatesUSD

Valuation

Price/book 0.9× against a median of 4.5×: 2nd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$29.89M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.22

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Compass Therapeutics, Inc. · NASDAQ:CMPXUS$123.9M−US$29.89Mn/an/an/a0.9×n/a0.1×1.22
Yoda Pharmaceuticals Inc. · TPEX:7829US$127.1MUS$94.37Mn/an/an/a3.9×n/a0.0×n/a
IntoCell, Inc. · KRX:287840US$126.6MUS$108.8Mn/a45.9×n/a8.7×−295.9%0.0×n/a
UnicoCell Biomed Co., Ltd. · TWSE:6794US$126.3MUS$106.5Mn/a117×n/a5.1×−381.5%0.1×n/a
MacroGenics, Inc. · NASDAQ:MGNXUS$125.3M−US$127.6Mn/a−0.9×n/a5.0×−34.6%1.4×0.83
PolyPid Ltd. · NASDAQ:PYPDUS$124.3MUS$119.3Mn/an/an/a23.1×n/a0.3×0.93
Humacyte, Inc. · NASDAQ:HUMAUS$123.7MUS$96.01Mn/a40.1×n/a6.8×n/a2.0×2.56
Biomm SA · BMFBOVESPA:BIOM3US$122.6MUS$136.5M18.4×2.1×12.3×2.2×10.3%0.3×n/a
Invivyd, Inc. · NASDAQ:IVVDUS$122.0MUS$3.86Mn/a0.1×n/a0.8×−214.8%0.1×2.06
Satellos Bioscience Inc · TSX:MSCLUS$121.9MUS$69.23Mn/an/an/a2.5×n/a0.0×0.49
Alar Pharmaceuticals Inc · TPEX:6785US$121.0MUS$51.66Mn/a568×n/a1.7×n/a0.0×n/a
Median of the othersUS$124.0MUS$95.19M18.4×40.1×12.3×4.5×−214.8%0.1×0.93

Forecasts

10 strong buy · 2 buy · 3 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
5.70 USD · Analysts' mean
EPS, year to Dec 2026
-0.48 · 8 analysts

Team and board

Officers

OfficerRole
James BoylanCEO, Enavate Sciences
Thomas J. SchuetzChief Executive Officer, Compass Therapeutics
Barry ShinChief Financial Officer
Richard S. LindahlExecutive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions
Mary Ann GrayPresident, Gray Strategic Advisors, LLC
Ellen V. ChiniaraChief Legal Officer and Corporate Secretary, Kymera Therapeutics
Jonathan AndermanSenior Vice President, General Counsel and Corporate Secretary
Ian ChiaVice President of Business Development & Strategy
James KranzVice President and Head of Chemistry Manufacturing and Controls
Karin HerreraSenior Vice President and Head of Clinical Operations
Kris SachsenmeierVice President of Translational Sciences
Neil LernerSenior Vice President, Chief Accounting Officer
Anna GiffordChief of Staff
Arjun PrasadChief Commercial Officer
Bing GongChief Scientific Officer
Carl GordonFounding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC
ContactAnna GiffordChief of
Cynthia SirardChief Medical Officer

Board

DirectorRole
Carl GordonFounding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC
Ellen V. ChiniaraChief Legal Officer and Corporate Secretary, Kymera Therapeutics
James BoylanCEO, Enavate Sciences
Mary Ann GrayPresident, Gray Strategic Advisors, LLC
Philip FerneauManaging Partner, Borealis Ventures
Richard S. LindahlExecutive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions
Thomas J. SchuetzChief Executive Officer, Compass Therapeutics

Events

Calls

CallWhenStatus
Compass Therapeutics (NASDAQ:CMPX) Q2 2025 Earnings CallMon, Aug 11, 2025 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 9, 2026 · Before open+10.3%
Q2 2026Aug 6, 2026 · Before open+5.3%
Q1 2026May 5, 2026 · Before open+0.5%
Q4 2025Feb 27, 2026−1.7%
Q3 2025Nov 5, 2025 · Before open+0.8%
Q2 2025Aug 11, 2025 · Before open+23.7%
Q1 2025May 8, 2025 · Before open+1.1%
Q4 2024Feb 28, 2025−6.5%
Q3 2024Nov 12, 2024 · Before open−5.8%
Q2 2024Aug 12, 2024 · Before open+3.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open−2.5%
Q4 2023Mar 21, 2024 · Before open+5.7%
Q3 2023Nov 9, 2023 · Before open−6.4%
Q2 2023Aug 3, 2023 · Before open+1.5%
Q1 2023May 4, 2023 · Before open−1.3%
Q4 2022Mar 15, 2023 · Before open−1.1%
Q3 2022Nov 9, 2022 · Before open−1.4%
Q2 2022Aug 1, 2022 · Before open+1.5%
Q1 2022May 9, 2022 · Before open−3.0%
Q4 2021Mar 18, 2022 · After close+6.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck45 slidesSeptember 2026
Investor Presentation (July 2026)Investor deck45 slidesJul 1, 2026
Investor Presentation (April 2026)Investor deck16 slidesApr 27, 2026
Q2 2025 Earnings PresentationEarnings18 slidesAug 11, 2025
Q2 2025 Earnings PresentationEarnings38 slidesAug 11, 2025
Investor Presentation (April 2025)Investor deck10 slidesApr 1, 2025
Technical Presentation (January 2023)Technical20 slidesJan 23, 2023
Investor Presentation (May 2022)Investor deck36 slidesMay 4, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: Jefferies +2
Dealers: Jefferies (co-lead), Piper Sandler (co-lead), Guggenheim Securities (co-lead)
Use of proceeds: Initial preparations for commercial readiness, research and clinical development of product candidates, and general corporate purposes
Aug 12, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY2019FY2018
Revenue0850.0K000000
Cost of revenue1.47M1.89M1.90M1.62M2.40M2.12M1.92M
Gross profit-1.47M850.0K-1.89M-1.90M-1.62M-2.40M-2.12M-1.92M
Research and development56.0M42.3M38.1M30.0M20.3M14.9M22.4M27.1M
Selling, general and administrative16.9M15.1M12.2M11.7M10.9M12.9M11.6M11.2M
Operating income-72.8M-56.6M-50.4M-41.7M-81.9M-27.8M-32.1K-34.1M-32.8K-38.3M
Depreciation and amortization276.0K589.0K699.0K782.0K600.0K2.40M2.10M1.92M
EBITDA-72.6M-56.0M-49.7M-40.9M-81.3M-25.4M-32.0M-36.4M
Interest expense0370.0K908.0K5.38K1.23M3.28K767.0K
Income before tax-66.5M-49.4M-42.5M-39.2M-82.2M-29.5M-34.7M-38.2M
Income tax0000032.0K91.0K103.0K
Net income-66.5M-49.4M-42.5M-39.2M-82.2M-29.5M-37.5K-34.7M-36.0K-38.3M
Earnings per share, basic-0.42-0.36-0.33-0.37-1.31-0.96-0.01-5.19-0.01-7.66
Earnings per share, diluted-1.31-0.96-0.01-5.19-0.01

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY2019FY2018
Cash and equivalents30.6M43.5M24.2M34.9M144.5M47.1M3.75K25.3M4.87K57.5M
Short-term investments178.3M83.2M128.2M151.7M0
Receivables320.0K
Current assets209.8M132.8M153.9M194.8M147.1M50.2M3.75K26.2M4.87K58.9M
Property, plant and equipment102.0K353.0K898.0K1.57M2.24M1.13M3.75M5.37M
Total assets219.6M140.4M156.9M199.6M153.8M51.9M3.75K30.4M4.87K64.6M
Accounts payable1.58M2.25M4.09M3.38M867.0K1.06M629.0K1.73M
Current liabilities14.0M8.87M7.80M16.2M10.6M10.1M111.8K9.82M75.5K8.46M
Long-term debt01.87M9.29M11.1M
Total debt9.83M6.63M1.73M2.94M09.33M14.9M14.8M
Total liabilities22.8M15.2M8.34M18.0M13.7M12.0M111.8K19.1M75.5K149.4M
Shareholders' equity196.8M125.2M148.5M181.6M140.1M39.9M-124.8M11.3M-95.3M-84.8M
Shares outstanding178.3M137.8M127.7M126.3M100.8M51.2M5.00M7.03M5.00M5.00M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2020FY2019FY2019FY2018
Cash from operations-49.1M-44.9M-40.6M-34.1M-19.7M-26.8M-32.1K-31.7M-32.8K-33.7M
Capital spending-25.0K-44.0K-30.0K-212.0K-1.57M-106.0K-466.0K-2.02M
Free cash flow-49.2M-44.9M-40.6M-34.3M-21.2M-26.9M-32.2M-35.7M
Cash from investing-93.3M46.8M27.0M-151.2M-1.77M38.0K-466.0K-2.02M
Cash from financing129.6M17.3M2.94M75.8M118.6M48.5M31.0K37.6K37.6K64.0M
Share buybacks-15975.8M128.0M54.2M
Change in cash-12.8M19.3M-10.7M-109.6M97.2M21.8M-1.12K-32.2M4.87K28.3M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 20, 2026Current reportSEC
4 · Change in ownershipNov 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
8-K · Current reportSep 22, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
8-K · Current reportJul 1, 2026Current reportSEC
8-K · Current reportJun 22, 2026Current reportSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
4/A · Change in ownership, amendedApr 30, 2026Insider tradeSEC
4/A · Change in ownership, amendedApr 30, 2026Insider tradeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
4 · Change in ownershipApr 29, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
8-K · Current reportApr 27, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveJan 8, 2026Other filingsSEC
8-K · Current reportJan 6, 2026ResultsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 5, 2026Insider tradeSEC
3 · Initial statement of ownershipJan 5, 2026Insider tradeSEC
CORRESP · Letter to the SECJan 5, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 2, 2026Other filingsSEC
DEL AMDec 31, 2025Other filingsSEC
S-3 · Registration statementDec 30, 2025Offer documentSEC
4 · Change in ownershipNov 18, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 29, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 21, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 18, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
8-K · Current reportAug 13, 2025Material contractSEC
424B5 · ProspectusAug 13, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
424B5 · ProspectusAug 12, 2025Offer documentSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
8-K · Current reportJun 12, 2025Meeting outcomeSEC
4 · Change in ownershipMay 27, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 11, 2025Big-stake noticeSEC
144 · Notice of proposed saleApr 9, 2025Other filingsSEC
144 · Notice of proposed saleApr 9, 2025Other filingsSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
8-K · Current reportApr 1, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 16, 2025Big-stake noticeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
8-K · Current reportJan 8, 2025ResultsSEC
4 · Change in ownershipDec 10, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 10, 2024Insider tradeSEC
3 · Initial statement of ownershipDec 10, 2024Insider tradeSEC
8-K · Current reportDec 10, 2024Management or board changeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveSep 9, 2024Other filingsSEC
CORRESP · Letter to the SECSep 4, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 3, 2024Other filingsSEC
S-3 · Registration statementAug 30, 2024Offer documentSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
3 · Initial statement of ownershipAug 9, 2024Insider tradeSEC
SC 13G · Big-stake noticeAug 2, 2024Big-stake noticeSEC
8-K · Current reportJun 17, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialMay 28, 2024Meeting noticeSEC
8-K · Current reportMay 28, 2024Management or board changeSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
8-K · Current reportMay 13, 2024ResultsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
8-K · Current reportApr 25, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMar 22, 2024Big-stake noticeSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 14, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
4 · Change in ownershipFeb 9, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 1, 2024Big-stake noticeSEC
4 · Change in ownershipJan 10, 2024Insider tradeSEC
4 · Change in ownershipJan 10, 2024Insider tradeSEC
8-K · Current reportJan 9, 2024Management or board changeSEC
8-K · Current reportJan 5, 2024ResultsSEC
SC 13G · Big-stake noticeNov 27, 2023Big-stake noticeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
10-Q · Quarterly reportAug 3, 2023Quarterly reportSEC
8-K · Current reportAug 3, 2023ResultsSEC
8-K · Current reportJun 15, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 4, 2023Quarterly reportSEC
8-K · Current reportMay 4, 2023ResultsSEC
ARS · Annual report to shareholdersApr 27, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2023Meeting noticeSEC
4 · Change in ownershipApr 24, 2023Insider tradeSEC
3 · Initial statement of ownershipApr 24, 2023Insider tradeSEC
8-K · Current reportApr 24, 2023Management or board changeSEC
10-K · Annual reportMar 15, 2023Annual reportSEC
4 · Change in ownershipMar 10, 2023Insider tradeSEC
8-K · Current reportMar 10, 2023Current reportSEC
4 · Change in ownershipFeb 27, 2023Insider tradeSEC
8-K · Current reportFeb 24, 2023Management or board changeSEC
4 · Change in ownershipFeb 15, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2023Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2023Insider tradeSEC
3 · Initial statement of ownershipFeb 10, 2023Insider tradeSEC
8-K · Current reportFeb 10, 2023Management or board changeSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
4 · Change in ownershipFeb 9, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
4 · Change in ownershipJan 31, 2023Insider tradeSEC
424B3 · ProspectusJan 24, 2023Offer documentSEC
4 · Change in ownershipJan 24, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveJan 23, 2023Other filingsSEC
8-K · Current reportJan 19, 2023Current reportSEC
CORRESP · Letter to the SECJan 19, 2023Other filingsSEC
CORRESP · Letter to the SECJan 17, 2023Other filingsSEC
CORRESP · Letter to the SECJan 13, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 7, 2022Other filingsSEC
S-3 · Registration statementDec 2, 2022Offer documentSEC
8-K · Current reportNov 29, 2022Management or board changeSEC
4 · Change in ownershipNov 25, 2022Insider tradeSEC
4 · Change in ownershipNov 22, 2022Insider tradeSEC

This page holds 200 of 364 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Compass Therapeutics, Inc.’s releases · as of Nov 5, 2026

Common shares
180,087,915
Fully diluted
180,087,915

Fully diluted

LineSharesAs of
Common shares180,087,915Nov 5, 2026

Share count over time

CountShares
Nov 5, 2026180,087,915

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Tang Capital Management LLC18M10.0%US$18.7MSep 30, 2026
Orbimed Advisors LLC15.2M8.5%US$15.8MSep 30, 2026
Montanova Capital, LLC14.3M8.0%US$14.9MSep 30, 2026
BlackRock11.4M6.3%US$11.9MSep 30, 2026
Vanguard9.11M5.1%US$9.47MSep 30, 2026
Enavate Sciences Gp, LLC7.79M4.3%US$8.1MSep 30, 2026
State Street7.74M4.3%US$8.05MSep 30, 2026
Palo Alto Investors LP7.15M4.0%US$7.43MSep 30, 2026
Millennium4.69M2.6%US$4.87MSep 30, 2026
Qube Research & Technologies Ltd4.17M2.3%US$4.34MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Geode Capital3.64M2.0%US$3.79MSep 30, 2026
Rock Springs Capital Management LP3.52M2.0%US$3.67MSep 30, 2026
Vivo Capital, LLC3.42M1.9%US$3.56MSep 30, 2026
Goldman Sachs3.39M1.9%US$3.53MSep 30, 2026
Blue Owl Capital Holdings LP3.15M1.8%US$3.28MSep 30, 2026
Hrt Financial LP2.66M1.5%US$2.77MSep 30, 2026
Acadian Asset Management LLC2.64M1.5%US$2.73MSep 30, 2026
Citadel2.14M1.2%US$2.22MSep 30, 2026
AQR Capital Management LLC1.98M1.1%US$2.05MSep 30, 2026
Fisher Asset Management, LLC1.95M1.1%US$2.02MSep 30, 2026
Fidelity1.8M1.00%US$1.87MSep 30, 2026
D. E. Shaw & Co., Inc.1.75M0.97%US$1.82MSep 30, 2026
Marshall Wace, LLP1.71M0.95%US$1.78MSep 30, 2026
Birchview Capital, LP1.57M0.87%US$1.64MSep 30, 2026
Morgan Stanley1.49M0.83%US$1.55MSep 30, 2026
Algert Global LLC1.46M0.81%US$1.52MSep 30, 2026
Squarepoint Ops LLC1.39M0.77%US$1.45MSep 30, 2026
Arrowstreet Capital, Limited Partnership1.21M0.67%US$1.26MSep 30, 2026
Northern Trust1.09M0.60%US$1.13MSep 30, 2026
Royce & Associates LP888K0.49%US$924KSep 30, 2026
Dimensional856K0.48%US$891KSep 30, 2026
Susquehanna776K0.43%US$807KSep 30, 2026
KVP Capital Advisors, LP771K0.43%US$802KSep 30, 2026
Two Sigma769K0.43%US$800KSep 30, 2026
CM Management, LLC750K0.42%US$780KSep 30, 2026
Burkehill Global Management, LP700K0.39%US$728KSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.677K0.38%US$704KSep 30, 2026
Quadrature Capital Ltd639K0.35%US$664KSep 30, 2026
Citigroup Inc615K0.34%US$640KSep 30, 2026
Exome Asset Management LLC511K0.28%US$532KSep 30, 2026
Walleye Capital LLC493K0.27%US$513KSep 30, 2026
Bank of America464K0.26%US$483KSep 30, 2026
Wellington459K0.25%US$477KSep 30, 2026
Jacobs Levy Equity Management, Inc449K0.25%US$467KSep 30, 2026
Schwab431K0.24%US$448KSep 30, 2026
UBS423K0.24%US$440KSep 30, 2026
Nuveen387K0.22%US$403KSep 30, 2026
Caption Management, LLC385K0.21%US$401KSep 30, 2026
Gsa Capital Partners LLP374K0.21%US$389KSep 30, 2026
BNY352K0.20%US$366KSep 30, 2026

This page holds 50 of 169 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF6.84M3.8%US$15MJun 30, 2026
Vanguard Total Stock Market Index Fund4.19M2.3%US$9.18MJun 30, 2026
iShares Russell 2000 ETF3.46M1.9%US$7.57MJun 30, 2026
Vanguard Extended Market Index Fund1.79M1.00%US$3.93MJun 30, 2026
Fidelity Small Cap Index Fund1.43M0.79%US$2.73MJul 31, 2026
iShares Russell 2000 Value ETF1.21M0.67%US$2.66MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF1.12M0.62%US$2.46MJun 30, 2026
Vanguard Explorer Fund963K0.53%US$1.84MJul 31, 2026
Fidelity Extended Market Index Fund799K0.44%US$1.9MMay 31, 2026
Small Company Growth Portfolio775K0.43%US$1.7MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
College Retirement Equities Fund - Total Global Stock Account720K0.40%US$1.58MJun 30, 2026
Vanguard Russell 2000 Index Fund664K0.37%US$1.58MMay 31, 2026
Vanguard U.S. Momentum Factor ETF590K0.33%US$1.4MMay 31, 2026
Vanguard Strategic Small-Cap Equity Fund496K0.28%US$1.09MJun 30, 2026
iShares Micro-Cap ETF441K0.24%US$965KJun 30, 2026
Goldman Sachs Small Cap Value Insights Fund417K0.23%US$796KJul 31, 2026
Vanguard Market Neutral Fund400K0.22%US$876KJun 30, 2026
JPMorgan Small Cap Value Fund325K0.18%US$713KJun 30, 2026
Royce Micro-Cap Fund323K0.18%US$708KJun 30, 2026
Schwab Small-Cap Index Fund322K0.18%US$616KJul 31, 2026
Fidelity Total Market Index Fund278K0.15%US$662KMay 31, 2026
iShares Core S&P Total U.S. Stock Market ETF243K0.14%US$532KJun 30, 2026
Fidelity Series Total Market Index Fund235K0.13%US$560KMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares232K0.13%US$444KJul 31, 2026
Master Small Cap Index Series221K0.12%US$485KJun 30, 2026
Meridian Small Cap Growth Fund212K0.12%US$464KJun 30, 2026
ALPS Medical Breakthroughs ETF186K0.10%US$442KMay 31, 2026
Fidelity Small Cap Value Index Fund183K0.10%US$401KJun 30, 2026
Dimensional U.S. Core Equity 2 ETF166K0.09%US$318KJul 31, 2026
Nuveen Small Cap Blend Index Fund159K0.09%US$303KJul 31, 2026
Virtus Biotech Clinical Trials Etf153K0.09%US$292KJul 31, 2026
Goldman Sachs Small Cap Equity Insights Fund144K0.08%US$275KJul 31, 2026
EQ/2000 Managed Volatility Portfolio144K0.08%US$314KJun 30, 2026
Nuveen Equity Index Fund121K0.07%US$231KJul 31, 2026
Fidelity Nasdaq Composite Index Fund109K0.06%US$260KMay 31, 2026
Schwab Total Stock Market Index Fund108K0.06%US$207KJul 31, 2026
Royce Capital Fund - Micro-Cap Portfolio107K0.06%US$234KJun 30, 2026
Dimensional U.S. Small Cap ETF101K0.06%US$193KJul 31, 2026
LVIP State Street Small-Cap Index Fund85,9400.05%US$188KJun 30, 2026
Optimize Strategy Index ETF80,1600.04%US$176KJun 30, 2026
JPMorgan Small Cap Value Portfolio80,0590.04%US$175KJun 30, 2026
EQ/Small Company Index Portfolio79,7500.04%US$175KJun 30, 2026
Fidelity ZERO Total Market Index Fund78,8570.04%US$151KJul 31, 2026
EQ/AB Small Cap Growth Portfolio73,6900.04%US$161KJun 30, 2026
JPMorgan U.S. Small Company Fund73,0740.04%US$160KJun 30, 2026
VIP Disciplined Small Cap Portfolio72,1920.04%US$158KJun 30, 2026
Clearwater Select Equity Fund70,3310.04%US$154KJun 30, 2026
Vanguard Balanced Index Fund69,5050.04%US$152KJun 30, 2026
Small Cap Index Fund67,9100.04%US$149KJun 30, 2026
Small Cap Value Fund66,2950.04%US$158KMay 31, 2026

This page holds 50 of 142 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Lerner Neil
Officer: Chief Accounting Officer
Buy10,000USD 0.59US$5,900Nov 17, 2026
Lerner Neil
Officer: Chief Accounting Officer
Buy20,000USD 0.92US$18,400Oct 1, 2026
Lerner Neil
Officer: Chief Accounting Officer
Buy2,500USD 1.14US$2,850Sep 24, 2026
Anderman Jonathan
Officer: General Counsel
Buy25,000USD 1.89US$47,250Apr 29, 2026
Lerner Neil
Officer: Chief Accounting Officer
Buy15,000USD 1.89US$28,350Apr 29, 2026

Big stakes

StakeStakeSharesDateFiling
Tang Capital Management LLC9.99%17.2MSep 30, 2025Schedule 13G
Orbimed Advisors LLC8.90%15.2MAug 13, 2025Schedule 13D
Montanova Capital, LLC8.20%14.1MAug 13, 2025Schedule 13G
BlackRock, Inc.5.20%9.27MDec 31, 2025Schedule 13G
Commander Aggregator, LP4.50%7.79MAug 14, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020
Ian Seth Jacobs
Other companies: Matternet Inc (President, CEO, CFO, Secretary, Director · Since at least Sep 30, 2025); Deep Fission, Inc. (President, CEO, CFO, Secretary, Director · Since at least Apr 20, 2022); Deep Isolation Nuclear, Inc. (President, CEO, CFO, Secretary, Director · Since at least Apr 20, 2022); Guerrilla RF, Inc (President, CEO, CFO, Secretary, Director · Mar 5, 2021 – Mar 5, 2021 · Past); Serve Robotics Inc. (President, CEO, CFO, Secretary, Director · Mar 5, 2021 – Mar 5, 2021 · Past); Aeluma, Inc. (President, Secretary, CEO, CFO, Director · Dec 1, 2020 – Dec 1, 2020 · Past); SmartKem, Inc. (President, Secretary, CEO, CFO, Director · Aug 17, 2020 – Aug 17, 2020 · Past); Augmedix Inc (President, Secretary CEO & CFO, Director · May 13, 2019 – May 13, 2019 · Past); Exicure, Inc. (President, Secretary, CEO, CFO, Director · May 20, 2017 – Sep 22, 2017 · Past)
President, Sec, CEO, & CFO, Director · Jul 29, 2018 – Jul 29, 2018 · Past
Mark N Tompkins
Other companies: Matternet Inc (Director · Since at least Sep 30, 2025); Deep Fission, Inc. (Director · Since at least Apr 20, 2022); Deep Isolation Nuclear, Inc. (Director · Since at least Apr 20, 2022); Guerrilla RF, Inc (Director · Mar 5, 2021 – Mar 5, 2021 · Past); Serve Robotics Inc. (Director · Mar 5, 2021 – Mar 5, 2021 · Past); Aeluma, Inc. (Director · Dec 1, 2020 – Dec 1, 2020 · Past); SmartKem, Inc. (Director · Aug 17, 2020 – Aug 17, 2020 · Past); Augmedix Inc (Director · May 13, 2019 – May 13, 2019 · Past)
Director · Jul 29, 2018 – Jul 29, 2018 · Past
Stephen P Squinto
Other companies: Chemomab Therapeutics Ltd. (Director · Mar 16, 2021 – Apr 19, 2021 · Past); Passage Bio, Inc. (Head of Research and Dev, Director · Feb 27, 2020 – Feb 27, 2020 · Past); SpringWorks Therapeutics Inc (Director · Mar 29, 2019 – May 19, 2022 · Past); Audentes Therapeutics Inc (Director · Jul 19, 2016 – Oct 8, 2017 · Past); Alexion Pharmaceuticals Inc (EVP, Chief Global Ops. Officer · Jan 9, 2006 – Oct 27, 2014 · Past)
Director · Jun 17, 2020 – Feb 18, 2022 · Past
Mary Ann Gray
Other companies: BioAtla, Inc. (Director · Since at least Jun 16, 2022); Keros Therapeutics, Inc. (Director · Since at least Jun 1, 2022); RAPT Therapeutics Inc (Director · Since at least Mar 31, 2022); Palisade Bio, Inc. (Director · Jun 11, 2023 – Nov 21, 2023 · Past)
Director · Since at least Apr 26, 2022
Miranda Toledano
Other companies: Entera Bio Ltd. (Chief Executive Officer and Board Member · Since at least Jan 1, 2022); Journey Medical Corporation (Director · Since at least Nov 16, 2021); NexGel, Inc (Director · Sep 9, 2021 – Aug 17, 2023 · Past); Sorrento Therapeutics, Inc. (EVP-Corporate Development · Sep 16, 2016 – Sep 16, 2016 · Past)
Director · Jun 25, 2021 – Jun 25, 2021 · Past
Ellen V. Chiniara
Other companies: Kymera Therapeutics, Inc. (Chief Legal Officer · Jan 3, 2023 – Mar 3, 2025 · Past); Alexion Pharmaceuticals Inc (EVP & Chief Legal Officer · Feb 12, 2018 – Jul 21, 2021 · Past); Alere Inc (GC, Chief Ethics Officer&Sec · Dec 31, 2010 – Oct 3, 2017 · Past)
Chief Legal Officer and Corporate Secretary, Kymera Therapeutics · Since at least Apr 26, 2022
James Boylan
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024); Zenas BioPharma, Inc. (Director · Since at least Sep 12, 2024); Immunome, Inc. (Director · Since at least Oct 2, 2023)
Director · Since at least Nov 4, 2022
Richard S. Lindahl
Other companies: Emergent BioSolutions Inc. (Executive Vice President · Since at least Mar 26, 2018); The Corporate Executive Board Company (Chief Financial Officer · Mar 27, 2013 – Apr 27, 2015 · Past); SPRINT Corp (Treasurer · Feb 7, 2006 – Aug 4, 2008 · Past)
Executive Vice President, Chief Financial Officer and Treasurer, Emergent BioSolutions · Since at least Apr 21, 2023
Brett Kaplan
Other companies: Climb Bio, Inc. (Chief Operating Officer · Aug 26, 2024 – Jan 13, 2025 · Past); Prevail Therapeutics Inc (Chief Financial Officer · Jun 19, 2019 – Jan 22, 2021 · Past)
Director · Sep 10, 2020 – Feb 18, 2022 · Past
All 28 people
PersonSeat
Thomas J. Schuetz
Other companies: Audentes Therapeutics Inc (Director · Jul 19, 2016 – Jan 15, 2020 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past)
Chief Executive Officer, Compass Therapeutics · Since at least Jun 17, 2020
Barry Shin
Other companies: Trevena, Inc. (Acting COO and CFO · Jun 25, 2019 – Oct 8, 2024 · Past)
Chief Financial Officer · Since at least Dec 9, 2024
Cynthia Sirard
Other companies: Cypherpunk Technologies Inc. (Chief Medical Officer · Apr 1, 2020 – Mar 28, 2025 · Past)
Chief Medical Officer · Since at least Jan 2, 2026
Vered Bisker-Leib
Other companies: Ayala Pharmaceuticals Inc (Director · Aug 18, 2020 – Jan 19, 2023 · Past)
CHIEF EXECUTIVE OFFICER, Director · Jun 17, 2020 – Feb 8, 2024 · Past
Anna GiffordChief of Staff · Since at least Nov 2, 2026
Arjun PrasadChief Commercial Officer · Since at least Jan 2, 2026
Bing GongChief Scientific Officer · Since at least Mar 5, 2026
ContactAnna GiffordChief of · Since at least Dec 17, 2025
David M WurzerDirector · Feb 8, 2023 – Feb 8, 2023 · Past
Ian ChiaVice President of Business Development & Strategy · Since at least Nov 4, 2026
James KranzVice President and Head of Chemistry Manufacturing and Controls · Since at least Nov 4, 2026
Jonathan AndermanSenior Vice President, General Counsel and Corporate Secretary · Since at least Aug 1, 2024
Julie SunderlandDirector · Jun 17, 2020 – Jun 19, 2020 · Past
Karin HerreraSenior Vice President and Head of Clinical Operations · Since at least Nov 4, 2026
Kris SachsenmeierVice President of Translational Sciences · Since at least Nov 4, 2026
Neil LernerSenior Vice President, Chief Accounting Officer · Since at least Dec 9, 2024
Philip FerneauManaging Partner, Borealis Ventures · Since at least Jun 17, 2020
Susan KalledChief Scientific Officer · May 3, 2021 – Feb 18, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Compass Therapeutics, Inc.